Chao Tai

Chao Tai has extensive work experience in the field of scientific research and drug development. They started their career as a Postdoctoral Fellow at the University of Washington in 2010, where they worked in the Department of Pharmacology until 2014. Following this, Chao joined the Gladstone Institutes as a Scientist in 2014 and continued in this role until 2020. During their time at Gladstone Institutes, Chao likely contributed to various research projects.

Chao then transitioned to Mitokinin Inc in 2020 and held two positions within the company. They initially served as a Scientist II from May 2020 to April 2021, where they likely contributed to the establishment of in vitro models for Parkinson's disease and neurodegenerative diseases. They then progressed to the role of Scientist III from May 2021 to April 2022, where they continued their work in developing in vitro models for disease research.

In 2022, Chao joined Encoded Therapeutics Inc as a Senior Scientist I. Given the recent start date, it is likely that Chao is currently contributing to ongoing research projects at the company, although specific details of their role and responsibilities are not available.

Chao Tai earned a Bachelor of Science (B.Sc.) degree in Physiology and Biophysics from Peking University, where they studied from 1998 to 2002. During the same period, they also obtained a Minor Diploma in Computer Software from Peking University. Chao Tai furthered their education by pursuing a Doctor of Philosophy (Ph.D.) degree in Neuroscience at The University of British Columbia, from 2003 to 2009.